Prostate cancer is one of the most common tumours in adult men and heat shock proteins play an important biological function in prostate cancer as molecular chaperones involved in the pathogenesis, diagnosis, treatment and prognosis of a wide range of tumours. Among them, increased expression of HSP90, a member of the heat shock protein family, is associated with resistance to prostate cancer denervation and can promote tumour resistance, invasion and bone metastasis, thus making prostate cancer more difficult to treat. Therefore, targeting HSP90 in prostate cancer could be a promising strategy for oncology treatment. This paper reviews the structure and function of HSP90, HSP90-mediated denudation resistance in prostate cancer and HSP90-targeted antitumor therapy, with the aim of providing a new theoretical basis for prostate cancer treatment options in the clinical setting.
Keywords: depot resistance; heat shock proteins 90; prostate cancer; review; tumour resistance.
© 2022 Wiley-VCH GmbH.